Aduro Biotech to Present at NASDAQ Investor Conference

- June 9th, 2016

June 09, 2016 08:00 ET | Source:Aduro Biotech, Inc. BERKELEY, Calif., June 09, 2016 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 34th NASDAQ Investor Conference on Thursday, June 16, 2016, at 10:15 am British Summer Time. To … Continued

| Source:Aduro Biotech, Inc.



BERKELEY, Calif., June 09, 2016 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 34th NASDAQ Investor Conference on Thursday, June 16, 2016, at 10:15 am British Summer Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro’s website at www.aduro.com.

About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro’s technology platforms, which are designed to harness the body’s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro’s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro’s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.

Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
Media Contact:
Angela Bitting
925 202 6211
press@aduro.com
Mike Beyer
Sam Brown, Inc.
312 961 2502
mikebeyer@sambrown.com

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply